Jefferies Adjusts Price Target on Moderna to $215
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
Stocks · News reference
Gainers Tenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.6 million. As per the news, the Q2 earnings report came
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.
Anthropic is set to go public on November 19, 2026, at a $1.33 trillion valuation with a proposed IPO price of $70-$78 per share. While the company shows explosive revenue growth (12-fold increase to $17B in Q3), its 38x price-to-sales valuation is expensive. Historical data shows the 10 largest U.S. IPOs since 2006 declined an average of 32% from their IPO price within the first year, suggesting investors should wait for better entry points rather than buying at the IPO.
Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Akanda Corp. has filed to sell 4.82 million common shares, marking a new equity financing action for the company.